(IN BRIEF) WACKER has launched a new Contract Research Services platform designed to support biotech and biopharma companies developing nucleic acid-based medicines, including RNA therapies, plasmid DNA technologies and lipid nanoparticle formulations. Operating from the company’s Biotechnology Center in Munich, … Read the full press release
Posted in Business, Chemicals, Economy, Financial, Germany, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Technology
Tagged advanced therapeutics, biopharma, biotechnology, biotechnology innovation, biotechnology research, circular RNA, clinical manufacturing, Contract Research Services, crs, drug development, gene therapy, GMP manufacturing, lipid nanoparticles, LNPs, mRNA, Munich, nucleic acid medicines, pDNA, pharmaceutical industry, plasmid DNA, PLASMITEC®, RNA engineering, RNA therapeutics, saRNA, self-amplifying RNA, SRTD Biotech GmbH, vaccine development, WACKER, Wacker Biotech, WACKER expands advanced therapeutics capabilities with integrated Contract Research Services offering, WACKER expands biotechnology services with new Contract Research Services platform for nucleic acid medicines, WACKER launches new biotechnology research platform for RNA and nucleic acid therapeutic development, WACKER strengthens global biotechnology services with scalable nucleic acid development solutions
(IN BRIEF) Boehringer Ingelheim has received approval from Japan’s Ministry of Health, Labour and Welfare for JASCAYD® (nerandomilast) to treat adults with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. The oral PDE4B inhibitor is the first therapy of its kind … Read the full press release
Posted in Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Technology
Tagged antifibrotic treatment, Arata Azuma, Boehringer Ingelheim, clinical trials, FIBRONEER, fibrosis treatment, forced vital capacity, idiopathic pulmonary fibrosis, immunomodulatory therapy, IPF, Japan Ministry of Health Labour and Welfare, JASCAYD, lung disease, lung function decline, MHLW, nerandomilast, PDE4B inhibitor, pharmaceutical industry, PPF, progressive pulmonary fibrosis, pulmonary fibrosis, rare diseases, respiratory health, respiratory medicine, Shashank Deshpande
(IN BRIEF) Sandoz has received European Commission approval for two biosimilar insulin products, Bysumlog® (insulin lispro) and Dazparda® (insulin aspart), for the treatment of diabetes mellitus across Europe. Developed by Gan & Lee Pharmaceuticals, the products are intended to improve … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged affordable medicines, Armin Metzger, biologic medicines, biosimilar market, biosimilar medicines, biosimilars, blood glucose management, Bysumlog, Bysumlog® and Dazparda® Approvals Mark Latest Expansion of Sandoz Diabetes Strategy, chronic disease, Dazparda, diabetes care, Diabetes Mellitus, diabetes prevalence, diabetes treatment, European Commission, European healthcare, Gan & Lee Pharmaceuticals, healthcare access, healthcare expenditure, Humalog, insulin analogues, insulin aspart, insulin lispro, insulin products, insulin therapy, NovoRapid, Ondibta, pharmaceutical approvals, pharmaceutical industry, Sandoz, Sandoz Strengthens Biosimilars Leadership Through New Diabetes Treatment Approvals
(IN BRIEF) The European Investment Bank will provide advisory support to Romanian pharmaceutical producer Antibiotice SA to strengthen its corporate governance framework and investment readiness. The cooperation aims to align the company’s operational and risk-management practices with international pharmaceutical industry … Read the full press release
Posted in Banks, Business, European Union, Financial, Industrial, Investment, Management, News, Pharma & Biotech, Romania
Tagged Antibiotice Advances Governance Modernization With European Investment Bank Advisory Agreement, Antibiotice SA, corporate governance, EIB, EIB Supports Romania’s Pharmaceutical Industry Through Strategic Cooperation With Antibiotice SA, European healthcare industry, European Investment Bank, European Investment Bank to advise Antibiotice on strengthening corporate governance and investment readiness in Romania, generic medicines, Healthcare, Healthcare Innovation, healthcare supply chain, Iasi, industrial competitiveness, InvestEU, investment capacity, Ioan Nani, Ioannis Tsakiris, Medicine Production, Nystatin, pharmaceutical exports, pharmaceutical industry, pharmaceutical manufacturing, pharmaceuticals, risk management, Romania, Romanian economy, strategic investments, sustainability, United States Pharmacopeia
(IN BRIEF) Roche has agreed to acquire PathAI to strengthen its digital pathology and AI-powered diagnostics capabilities. The deal builds on an existing partnership between the companies focused on AI-enabled companion diagnostics and pathology solutions. Roche said the acquisition will … Read the full press release
Posted in Artificial Intelligence (AI), Business, Financial, Industrial, Infrastructure & Utilities, Investment, Management, Marketing, Pharma & Biotech, Science, Switzerland, Technology
Tagged AI diagnostics, AI-powered pathology, AISight, Andy Beck, artificial intelligence, Biomarker Development, biomarker discovery, Biopharma Industry, cancer diagnosis, clinical trials, companion diagnostics, Diagnostic Tools, diagnostics division, digital pathology, Healthcare Innovation, healthcare technology, image management system, laboratory automation, Matt Sause, medical AI, medical imaging, oncology diagnostics, PathAI, pathology laboratories, pathology software, personalized healthcare, pharmaceutical industry, precision medicine, Roche, Roche and PathAI Combination Aims to Accelerate Personalized Cancer Diagnostics and Biomarker Discovery, Roche Deepens Investment in Artificial Intelligence Through Planned PathAI Acquisition, translational research
(IN BRIEF) Sandoz is celebrating 20 years since the approval of Omnitrope, the world’s first biosimilar medicine, which helped establish a new pharmaceutical category and expand patient access to biologic treatments. Since its launch, Omnitrope has generated significant healthcare savings … Read the full press release
Posted in Business, Environment, Financial, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged Alfred Kern, biologics, biosimilar market, biosimilars, drug development, Edouard Sandoz, European Medicines Agency, global healthcare, growth hormone therapy, healthcare savings, Omnitrope, Omnitrope Anniversary Underscores Sandoz Leadership and Future Potential of Biosimilars in Transforming Patient Access, patient access, pharmaceutical industry, Richard Saynor, Sandoz, somatropin
(IN BRIEF) EQT Life Sciences has exited its investment in Tubulis following Gilead Sciences’ agreement to acquire the German biotechnology company in a deal valued at up to $5 billion including milestones. EQT supported Tubulis’ development into a clinical-stage oncology … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Sweden, Technology
Tagged ADC platform, antibody-drug conjugates, biotechnology acquisition, Cancer Therapies, Christoph Broja, clinical-stage biotech, Dominik Schumacher, EQT Life Sciences, EQT Life Sciences Realizes Investment Success with Sale of Tubulis to Gilead Sciences, EQT Life Sciences Supports Growth of Tubulis Leading to Major Acquisition by Gilead Sciences, Gilead Sciences, Munich biotech, oncology investment, pharmaceutical industry, Tubulis
(IN BRIEF) GSK has entered an agreement to acquire Canadian biotechnology company 35Pharma for $950 million in order to strengthen its pipeline of therapies for pulmonary hypertension and related cardiopulmonary diseases. The acquisition includes HS235, an investigational activin signalling inhibitor … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Technology, United Kingdom
Tagged 35Pharma, activin signalling inhibitor, biotechnology acquisition, CANADA, cardiopulmonary diseases, clinical trials, drug development, GSK, GSK Targets Next Generation Pulmonary Hypertension Treatments with Acquisition of 35Pharma, GSK to Acquire 35Pharma for 950 Million Dollars to Strengthen Pulmonary Hypertension Drug Pipeline, HS235, Ilia Tikhomirov, PH-HFpEF, pharmaceutical industry, pulmonary arterial hypertension PAH, pulmonary hypertension, Respiratory Immunology and Inflammation portfolio, Tony Wood
(IN BRIEF) Krka has been recognised as Slovenia’s leading company in the 2025 Business Excellence survey conducted by Ninamedia, ranking first among 54 companies according to both business representatives and the general public based on evaluations of visibility, performance, reputation, … Read the full press release
Posted in Awards, Business, Environment, Financial, Industrial, Investment, Management, News, Pharma & Biotech, Science, Slovenia, Technology
Tagged business performance, company visibility, Corporate Leadership, corporate reputation, INNOVATION, international expansion, Jože Colarič, Krka, Krka Recognised as Slovenia’s Leading Company in 2025 Business Excellence Survey by Ninamedia, Ninamedia, pharmaceutical industry, Slovenian business excellence, Slovenian exporters, sustainability
(IN BRIEF) GSK and Shionogi have agreed with Pfizer to restructure ViiV Healthcare’s shareholder base, with Shionogi replacing Pfizer’s 11.7 percent economic interest and increasing its stake to 21.7 percent, while GSK maintains a 78.3 percent majority holding. The transaction, … Read the full press release
Posted in Business, Healthcare, Investment, Pharma & Biotech, Science, Technology, United Kingdom
Tagged biopharma partnership, cabotegravir, David Redfern, dolutegravir, GSK, HIV prevention, HIV treatment, integrase inhibitors, John Keller, long acting injectables, Pfizer, pharmaceutical industry, shareholder restructuring, Shionogi, strategic investment, ViiV Healthcare, ViiV Healthcare Ownership Streamlined with Expanded Shionogi Investment and GSK Majority
(IN BRIEF) GEA has joined the DAX index, becoming one of Germany’s 40 largest listed companies following a strong rise in its market valuation and successful qualification via Deutsche Börse’s “Fast Entry” process. The company’s transformation, centered on innovation, sustainability, … Read the full press release
Posted in Business, Electronics & Machinery, Environment, Financial, Food & Beverage, Germany, Government, Industrial, Investment, Management, Marketing, News, Technology
Tagged AI, automation, Beverage Industry, DAX, DAX 50 ESG, Deutsche Börse, Dow Jones Best-in-Class World, Düsseldorf, energy efficiency, food industry, GEA, Industrial Machinery, ISS STOXX, MDAX, Mission 26, Mission 30, new food, partnership, pharmaceutical industry, Stefan Klebert, stock market index, sustainability, TIME Magazine
(IN BRIEF) SCHOTT Pharma has begun construction on a new production facility for ready-to-use (RTU) cartridges at its Lukácsháza site in Hungary. The investment of over 100 million euros will expand the company’s manufacturing capacity to meet increasing demand for … Read the full press release
Posted in Business, Environment, Financial, Germany, Government, Healthcare, Hungary, Industrial, Infrastructure & Utilities, Investment, Management, Marketing, News, Pharma & Biotech, Science, Technology
Tagged Andreas Reisse, biologics, Diabetes, Eva Szabó, expansion, GLP-1 drugs, high-value solutions, hormone therapies, Hungary, insulin, investment, Lukácsháza, manufacturing capacity, Ministry of Foreign Affairs and Trade, Obesity, partnership, pharmaceutical industry, pharmaceutical packaging, ready-to-use cartridges, SCHOTT Pharma, sterile cartridges, sustainability, sustainable development
(IN BRIEF) CVC Strategic Opportunities II has successfully exited its investment in Genetic S.p.A., a pharmaceutical CDMO specializing in Respiratory, Ophthalmic, and Oncology therapeutic products. The exit sees NB Renaissance and NB Aurora joining the Pavese family as shareholders. Under … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Italy, Luxembourg, Management, Marketing, News, Pharma & Biotech, Science, Technology
Tagged CVC Strategic Opportunities II, exit, FRM Tax, Genetic S.p.A., international expansion, investment, NB Aurora, NB Renaissance, oncology, Ophthalmic, partnership, Pavese family, PedersoliGattai, pharmaceutical CDMO, pharmaceutical industry, Product Development, PwC, respiratory, Rocco Pavese, Rothschild & Co., strategic growth
(IN BRIEF) ASSA ABLOY has signed an agreement to acquire Door System, a Danish manufacturer of high-quality fire-rated doors for the pharmaceutical, food, and retail sectors. Based in Hørning and employing 80 people, Door System is known for its innovative … Read the full press release
Posted in Business, Denmark, Financial, Government, Industrial, Infrastructure & Utilities, Investment, Management, News, Security & Safety, Sweden, Technology
Tagged ASSA ABLOY, Danish manufacturing, Denmark, door solutions, Door System, EMEIA Division, EPS accretive, fire-rated doors, food industry, freezer doors, hygienic doors, Hørning, industrial doors, Neil Vann, Nico Delvaux, partnership, pharmaceutical industry, retail sector, safety doors, Strategic Acquisition
(IN BRIEF) The University of Liverpool is leading two critical projects focused on decarbonising healthcare. The Greener Trials project, led by Professor Paula Williamson, aims to reduce the carbon footprint of clinical trials through an open science approach, collaborating with … Read the full press release
Posted in Business, Education, Environment, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged carbon footprint, carbon hotspots, clinical research, clinical trials, decarbonisation, Emissions Reduction, Greener Trials, healthcare sustainability, National Institute for Health and Care Research, net zero, NHS, NHS carbon footprint, One Health Systems, Open Science, pharmaceutical industry, Professor Paula Williamson, Professor Tim Jones, South African Medical Research Council, sustainability in healthcare, Sustainable Healthcare Coalition, UK healthcare, UK Research and Innovation, University of Exeter, University of Liverpool, Wellcome
(IN BRIEF) Basilea Pharmaceutica Ltd announced that its antifungal drug, Cresemba® (isavuconazole), surpassed sales targets in Japan, triggering a CHF 1.2 million sales milestone payment from its partner Asahi Kasei Pharma. This achievement, reached in just the second year of … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged Antifungal Drug, Asahi Kasei Pharma, Basilea Pharmaceutica Ltd, CHF 1.2 million, commercialization, Cresemba®, David Veitch, fungal infections, global sales, invasive fungal infections, Isavuconazole, Japan, market data, Market Growth, pharmaceutical industry, sales milestone
(IN BRIEF) Krka achieved a score of 56 out of 100 in the 2024 S&P Global Corporate Sustainability Assessment, ranking the company among the top 10% of pharmaceutical firms. This marks an improvement over the previous year’s performance and highlights … Read the full press release
Posted in Awards, Business, Environment, Financial, Industrial, Investment, Management, News, Pharma & Biotech, Science, Slovenia, Technology
Tagged Awards, business ethics, environmental protection, ESG, good manufacturing practice, Governance, health and well-being, integrity, Krka, leadership, patient care, pharmaceutical industry, quality medicines, S&P Global Corporate Sustainability Assessment, social responsibility, sustainability, transparent operations
(PRESS RELEASE) PARMA, Italy, 16-Apr-2020 — /EuropaWire/ — Triton announces that Bormioli Pharma has successfully completed the acquisition of 100% of GCL Pharma. The Italian company based in Vasto (Chieti), previously part of Guala Closures Group, specializes in the production … Read the full press release
NUREMBERG, 07-Feb-2018 — /EuropaWire/ — Siemens AG and Perceptive Engineering Ltd announce a partnership which offers Perceptive’s PharmaMV and Siemens Simatic Sipat software products closely integrated to provide a versatile solution for advanced control and optimization applications in both continuous and … Read the full press release
Posted in Germany, Pharma & Biotech, Technology
Tagged Perceptive Engineering, pharmaceutical industry, Siemens, Simatic, software solution
BRUSSELS, Belgium and MILAN, Italy, 09-May-2016 — /EuropaWire/ — Systech International, a global leader in brand protection technologies, will now offer its UniSolveTM serialization software as an integrated solution with labeling hardware from Etipack, a manufacturer of labeling and coding … Read the full press release
Posted in Belgium, Italy, Management, News, Pharma & Biotech, Technology, Transportation & Logistics
Tagged ampoules, brand protection, direct printing, EMEA, Etipack, flat cartons, formed cartons, labeling, labeling hardware, Manfred Voglmaier, packaging solutions, Pharmaceutical, pharmaceutical industry, print applications, Riccardo A. de Ferrari, serialization software, supply chain, Systech, Systech International, traceability, UniSolve™, vials
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?